TROG Cancer Research
Members Login   CQMS Login  

Become a TROG member

Do you have a professional interest in radiotherapy research?

Join the Trans Tasman Radiation Oncology Group (TROG Cancer Research)

Half of all people diagnosed with cancer would benefit from radiotherapy. The Trans Tasman Radiation Oncology Group (TROG Cancer Research) is the peak Australasian body for research into this safe and effective treatment. TROG is currently the highest recruiting collaborative trials group in Australia.

Become a member - it's FREE!

Become part of our network of more than 1,400 professionals in this exciting field.

Affiliate membership is FREE and open to anyone qualified or training in a radiotherapy-related discipline.

By joining, you’ll help advance clinical research into a treatment that benefits many cancers including breast, skin, lung, prostate and bladder, gynaecological, and head and neck.

  • Network with like-minded professionals
  • Stay up-to-date with industry news and trial updates in our monthly eNews
  • Access trial resources and Quality Assurance resources
  • Utilise the knowledge of TROG’s specialised committees

Or become a full member

Anyone fully qualified in their discipline, including radiation oncologists, medical oncologists, radiation therapists, medical physicists, statisticians, data managers, nurses and surgeons, can become a full TROG member.

For just $180+gst per year, full members hold voting rights at TROG meetings; can submit proposals for new trials; or become a Board member or Trial Chair.

  • Receive support at all stages of your trial’s development
  • Strengthen your grant application by aligning with TROG
  • Hold voting rights on trial protocols and other policies
  • Ensure treatment is safely administered via our QA program

All TROG members have access to the information in the members' section of the website, which includes the TROG Member Forum, Member directory and Member messenger; minutes and presentations from TROG meetings; copies of trial protocols; and the TROG Policy & Procedures Manual.

> Download TROG Membership Benefits poster

Register now

Applications for membership require a personal recommendation by two full members (a Proposer and a Seconder). Once you have identified two full members who will nominate you for membership, the application process simply involves choosing the nominating members from the list of Full Members in the online registration form (click on Register Now button below). The nominating members will by contacted by TROG Central Operations to confirm their support for your membership application.

Member guarantee

TROG is a company limited by guarantee under the Corporations Act. The liability of members is limited to payment of a nominal guarantee of A$10 in the event that the company is wound up. If required, this contribution would support payment of the debts and liabilities of the company, including the costs of the winding up.  By subscribing as a full member of TROG you undertake to provide this guarantee in the amount of A$10, if required. This undertaking continues for one year after a member ceases to be a member of the company.

 

TROG conducts world-class research in radiotherapy-based clinical trials.


Latest News

  • 11 Oct 2017

    figure>_ alt="file 20171009 25784 3p8oeb.png?ixlib=rb 1.1" src="https://images.theconversation.com/files/189307/original/file-20171009-25784-3p8oeb.png?ixlib=rb-1.1.0&q=45&auto=format&w=754" /> figcaption>randomisation is the only commonly accepted method of ensuring an unbiased esti...

  • 11 Oct 2017

    more than 65 people showed their support for cancer research by attending a high tea fundraising event hosted by trog cancer research. the event was held in newcastle, where the trog cancer research has its headquarters. on top of a delicious high tea, guests also took part in a silen...

  • 06 Oct 2017

    the trillions of bacteria living in our gut (called the gut microbiota) can help determine our risk of cancer, as well as how we might respond to cancer treatment. each person’s unique gut microbiota is in constant . this ensures good bacteria can thrive in the _, while bad bacteria a...

  • 12 Sep 2017

    trog cancer research is pleased to announce the appointment of john cleary to its board. ceo joan torony said that john was a perfect fit for trog’s board as he has more than 20 years’ experience at a senior management and executive level in both the not-for-profit and for-profit indu...

  • 17 Jul 2017

    p style="text-align: center;">_ src="/sitefiles/trogcomau/julie_with_mask.jpg" style="height: 338px; width: 600px;" /> trog cancer research is excited to announce julie mccrossin, well-known and respected broadcaster, journalist and former tv host, as its new ambassador. julie has ...

  • 17 Jul 2017

    alex carmichael has always been a busy man. during his career he was an executive working for many major australian companies. he's also served as a director of public companies and on the board of many government organisations. he's always been interested in building a better society...

  • 04 Jul 2017

    margaret and narelle first met when they were in year four at primary school. the pair have stayed friends since this time and now they are embarking on a trip of a life-time - trekking the wilds of tasmania, raising vital funds for cancer research. margaret and narelle have decide...

  • 16 Jun 2017

    patients with advanced skin cancer can now be spared from having to undergo chemotherapy, with results from a new australian study showing that surgery combined with radiotherapy is a more effective treatment. professor sandro porceddu who headed the trog cancer research ‘post’ tri...

  • 13 Jun 2017

    westmead hospital is now home to a world-first prostate cancer trial, using revolutionary technology to dramatically slash treatment times. the hospital is the first site in western sydney to run the spark clinical trial. trog's spark trial is underway in several nsw hospitals. it ...

  • 30 May 2017

    in a brain cancer breakthrough, an international clinical trial , has found that adding temozolomide chemotherapy during short-course radiation therapy, followed by monthly maintenance doses of temozolomide, significantly improved survival of elderly patients with glioblastoma (gbm), ...

  • 30 May 2017

    in a world-first breakthrough for early stage low-grade lymphoma, set to change the management of the disease worldwide, an international clinical trial has found that patients live longer when immuno-chemotherapy is combined with radiotherapy. the results of the international phas...